Insider Buying: HEDRICK MARC H, Plus Therapeutics Inc. [PSTV] Chief Executive Officer invested 5,000 shares

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Plus Therapeutics Inc. shares valued at $3,240 were purchased by HEDRICK MARC H on Jun 15. At $0.65 per share, HEDRICK MARC H acquired 5,000 shares. The insider’s holdings grew to 33,580 shares worth approximately $16454.2 following the completion of this transaction.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


Also, Clowes Howard purchased 15,000 shares, netting a total of over 8,589 in proceeds. Following the buying of shares at $0.57 each, the insider now holds 18,000 shares.

Before that, Petersen Greg had added 30,000 shares to its account. In a trade valued at $16,500, the Director bought Plus Therapeutics Inc. shares for $0.55 each. Upon closing the transaction, the insider’s holdings increased to 30,000 shares, worth approximately $30625.0.

As published in their initiating research note from Ladenburg Thalmann on January 25, 2021, Plus Therapeutics Inc. [PSTV] has been a Buy and the price target has been revised to $8. This represents a 93.88% premium over Thursday’s closing price. Analysts at Maxim Group started covering the stock with ‘”a Buy”‘ outlook in a report released in mid October.

Analyzing PSTV’s Price Performance

On Thursday, Plus Therapeutics Inc. [NASDAQ: PSTV] plunged -0.19% to $0.49. The stock’s lowest price that day was $0.46, but it reached a high of $0.525 in the same session. During the last five days, there has been a drop of approximately -21.68%. Over the course of the year, Plus Therapeutics Inc. shares have dropped approximately -53.80%. Shares of the company reached a 52-week high of $2.1600 on 01/04/22 and a 52-week low of $0.3901 on 07/18/22. A 50-day SMA is recorded $0.6193, while a 200-day SMA reached $0.8017. Nevertheless, trading volume fell to 3.0 million shares from 0.69 million shares the previous day.

Support And Resistance Levels for Plus Therapeutics Inc. (PSTV)

According to the 24-hour chart, there is a support level at 0.4551, which, if violated, would cause prices to drop to 0.4250. In the upper region, resistance lies at 0.5201. The next price resistance is at 0.5550. RSI (Relative Strength Index) is 34.50 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.1389, which suggests the price will decrease in the coming days. Percent R is at 93.72%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Plus Therapeutics Inc. subject to short interest?

Stocks of Plus Therapeutics Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 31670.0 shares to 44620.0. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 12950.0 shares. A jump of 70.98% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.75 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.75.

Which companies own the most shares of Plus Therapeutics Inc. (PSTV)?

According to Parkman Healthcare Partners LLC filings, the company currently owns 1,533,075 shares, which is about 6.64% of the total PSTV shares outstanding. The investor’s shares have appreciated by 6,759 from its previous 13-F filing of 1526316.0 shares. Otter Creek Advisors LLC acquire a 293.52% interest valued at $0.28 million while Geode Capital Management LLC 0 stake. In its current portfolio, Renaissance Technologies LLC holds 101,093 shares valued at $84817.0.


Please enter your comment!
Please enter your name here